• Careers

  • News

  • Connect with Us

  • Careers

  • News

  • Connect with Us

  • Useful Links

  • Change Region

  • Privacy Policy

  • Terms of Use

Focus Areas

                                                                                                                          

  
  

Heart & Metabolic Diseases

We are dedicated to developing therapies to treat, slow, or prevent disease progression and improve the quality of life for patients with obesity, type 2 diabetes (T2D), and cardiovascular (CV) and kidney diseases.

For more than 50 years, Pfizer has led the way in redefining the management of cardiovascular risk by bringing much-needed treatments to patients.

Today, Pfizer is focused on investigating potential therapies that treat both the metabolic abnormalities that increase the likelihood of cardiovascular disease and the heart itself by trying to alter the way it responds to the abnormal metabolic state. This includes more targeted potential therapies, as well as possible therapies that are a combination of two or more drugs, which could bring additional benefits to patients.

Our early discovery efforts focus on emerging areas of CV research such as control of eating disorders, type 2 diabetes/muscle uptake of glucose and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.

PP-CPF-HKG-0175
  • Focus Areas

  • Internal Medicine

  • Inflammation & Immunology

  • Oncology

  • Rare Disease

  • Vaccines

  • Anti-Infectives

  • Medicine Safety

  • Product Listing

  • Product Verification

  
  
Your HealthPatient Centered HealthcarePatient AccessDrug Handling TipsConsultation TipsOur PurposeHistoryBreakthroughs that change patients' lives
Culture
Pfizer Hong KongAwards
OUR ProductsFocus AreasMedicine SafetyProduct ListingProduct Verificationour scienceResearch and DevelopmentMedicines DevelopmentQuality MedicineQuality Managementour communityPatient CenteredGlobal Health FellowEnvironmental CareCommunity Team